Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineSotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer

In this single-group, phase 1-2 trial, sotorasib (LUMAKRAS, Amgen) demonstrated antitumor effect in patients with KRAS p.G12C-mutated advanced pancreatic cancer who had undergone prior therapy and had an acceptable safety profile.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form